Many tumors overexpress mutant forms of p53. A growing number of studies suggest that the nature of a p53 mutation in a cell can impact upon cellular properties, clinical responses to therapy and prognosis of a tumor. To explore the cellular basis of these observations, experiments were designed to compare the properties of cells with and without p53 mutations within the same cell population. To that end, various tumorderived human p53 mutants were introduced into p53-null H1299 lung adenocarcinoma cells. Clonogenic survival assays revealed that cells overexpressing the p53His175 mutant, but not the p53His273 mutant, recover preferentially from etoposide treatment. Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective eect. In contrast, p53His175 and p53His273 exerted very similar eects on the cellular response to cisplatin; both conferred increased resistance to low concentrations of the drug (2.5 mg/ml), but did not protect at all against high concentrations (10 mg/ml). Hence particular p53 mutants may confer upon tumor cells a selective survival advantage during chemotherapy. These ®ndings de®ne a new type of mutant p53 selective gain of function, which may compromise the ecacy of cancer chemotherapy.
Introduction
The p53 tumor suppressor gene is the most frequent target for genetic alterations in human cancer (Hollstein et al., 1997) . The wild type (wt) p53 protein can exert a variety of anti-proliferative eects, including induction of cell cycle arrest and of apoptosis (Levine, 1997; Hansen and Oren, 1997) . These eects are usually evident in cells exposed to DNA damage and other types of stress, which impinge on the otherwise latent p53 protein and cause its accumulation and biochemical activation (Levine, 1997; Hansen and Oren, 1997) . The therapeutic ecacy of anti-cancer agents depends strongly on their ability to trigger apoptosis in target tumor cells (Fisher, 1994) . Many physical and chemical DNA damaging agents used routinely in cancer therapy are potent p53 activators (Kastan et al., 1991; Fritsche et al., 1993; Zhan et al., 1993) . Given the documented contribution of p53 to radiation-induced apoptosis (Clarke et al., 1993; Lowe et al., 1993) , it was conceivable that cells maintaining functional wt p53 will be more prone to killing by many anti-cancer agents. Numerous subsequent basic and clinical studies have provided further support for this notion (Lowe, 1995) .
In human tumors, the majority of p53 gene alterations are missense mutations, often within the conserved DNA binding core domain of the protein (Levine, 1997; Hansen and Oren 1997) . The primary selective advantage of such mutations may well be the elimination of cellular wt p53 activity. However, at variance with the observations for several other tumor suppressor genes, cells with p53 mutations typically maintain expression of full length mutant protein, often at markedly elevated levels. This suggests that at least certain mutant forms of p53 may possess a gain of function, whereby they contribute positively to cancer progression (Michalovitz et al., 1991) . Since p53 mutants can also exert negative dominant eects on co-expressed wt p53, formal evidence for gain of function can only be obtained by introduction of mutant p53 into cells lacking p53 altogether (Michalovitz et al., 1991) . Such evidence has been provided through a combination of in vitro (Dittmer et al., 1993) and in vivo (Dittmer et al., 1993; Wolf et al., 1984; Hsiao et al., 1994) studies, where mutant p53 proteins conferred transformed properties in culture and greater tumorigenicity in mice.
Extensive attempts have been made to correlate p53 status with prognosis and therapy response of cancer patients. The presence of p53 mutations was found to predict worse prognosis and reduced response to therapy in many (Lowe, 1995; El Rouby et al., 1993; Wattel et al., 1994; Rusch et al., 1995; Righetti et al., 1996; Traubert et al., 1996; Hamada et al., 1996; Goh et al., 1995) , though not all (Makris et al., 1995; Mathieu et al., 1995; Cote et al., 1997) , tumors. Loss of wt p53 activity could potentially account fully for the increased radio-and chemoresistance of tumors bearing p53 mutations. Nevertheless, if one accepts the existence of gain of function p53 mutations, it might be reasoned that some of the apparent increased resistance to therapy may be due to direct protective eects of mutant p53 proteins. In fact, the behavior of leukemic mouse cells expressing a temperature sensitive p53 mutant is consistent with this notion (Lotem and Sachs 1995; Peled et al., 1996) . We therefore introduced several human tumorderived p53 mutants into p53-null H1299 lung adenocarcinoma cells. Clonogenic survival assays revealed that cells overexpressing mutant p53 proteins became more refractory to the cytotoxic eects of chemotherapeutic drugs. This appears due, at least in part, to the ability of the mutant p53 proteins to confer increased resistance against drug-induced apoptosis. Importantly, the protective eect was mutant-and drug-speci®c. Thus, p53His175 and p53His179 provided substantial resistance to etoposide, whereas the protective eect of p53His273 and p53Trp248 was much milder. On the other hand, p53His175 and p53His273 exerted practically identical eects on the response to cisplatin; both mutants enhanced markedly clonogenic survival and inhibited apoptosis when cells were treated with low drug concentrations, but had no eect in the presence of high concentrations.
Overall, these ®ndings suggest that overexpression of at least some forms of mutant p53 may directly enhance the resistance of tumor cells to anti-cancer agents, in a manner that depends on both the particular mutation and the identity of the drug. Such selective gain of function might contribute to the failure of chemotherapy.
Results

Generation of H1299 cell populations expressing p53 mutants
To study mutant p53 gain of function, various tumorderived p53 mutants were transfected into the p53-null human lung adenocarcinoma H1299 cell line (Mitsudomi et al., 1992) . Two strategies were employed to avoid undesirable clonal variations. In one approach cells were transfected stably and several tens of colonies were harvested together and maintained thereafter as a mixed pool. For each p53 mutant, two independent pools were established and analysed in parallel. In an alternative approach, transiently transfected cultures were analysed directly.
All stably transfected pools overexpressed comparable levels of the corresponding mutant p53 proteins, whereas H1299 cells transfected with vector alone were negative for p53 ( Figure 1a ). Immunostaining ( Figure  1b ) revealed a predominant nuclear localization of all mutants. Of note, only some of the cells in each pool were positive for p53, suggesting that the rest of the cells carry only drug resistance. The p53-positive fraction was about 30 ± 40%, as determined by staining for p53 followed by FACS analysis (data not shown).
Etoposide promotes selective enrichment of p53His175-overexpressing cells
If mutant p53 can provide increased chemoresistance, one might expect that treatment of a mixed population with appropriate cytotoxic drugs will enrich selectively for tumor cells overexpressing such mutant protein. To test this notion, we took advantage of the fact that only about a third of the cells in each stably transfected pool actually overexpressed p53. Pools of H1299 cells, transfected with either p53His175 or p53His273, were subjected to a clonogenic survival assay with or without addition of the anti-cancer drug etoposide, an inhibitor of topoisomerase II. Treatment with etoposide (10 mM ®nal concentration) lasted 48 hours. The drug was then washed away and cultures allowed to recover for another 14 days, giving rise to growing colonies. At the end of this period, cultures were ®xed and individual colonies were scored by immunostaining for mutant p53 expression. Three types of colonies were observed: those in which 90% or more of the cells stained strongly (denoted +/+ in Figure 2a Figure 5b), those in which all cells were negative for p53 (denoted 7/7), and an intermediate type where only a minority of the cells were strongly stained, typically at the center of the colony, suggesting loss of p53 expression during colony outgrowth (+/7). When p53His273 transfectants (Figure 2a , H-273) were plated at low density without etoposide selection, about 30% of the emerging colonies exhibited extensive mutant p53 overexpression (empty bars, +/+), whereas over half of the colonies were practically p53-negative (empty bars, 7/7). This corresponds very closely to the percentage of p53-positive cells within the pool at the beginning at the experiment, indicating that the presence of mutant p53 has no eect on the cloning eciency under non-stressed conditions. Etoposide treatment resulted in a dramatic reduction in the overall eciency of colony formation (data not shown), indicating that the majority of cells in the treated pool had been damaged beyond recovery. Yet, among the colonies which did eventually emerge, the pattern of mutant p53 overexpression was practically identical to the untreated culture ( Figure ) were plated at low density, and one week later were ®xed, stained with a mixture of Pab1801 and DO-1 and scored microscopically for p53 expression. Cultures to be treated (®lled bars) were plated at a higher cell density (see Materials and methods), incubated in the presence of 10 mM etoposide for 48 h and then allowed to resume growth without etoposide for another 2 weeks, at which time they were processed for p53 analysis as above. Individual colonies could be grouped into three categories, based on their p53 staining pattern. The ®rst group (+/+) included colonies consisting of 90 ± 100% p53-positive cells, the second (7/7) consisted of only p53-negative cells, and the intermediate category (+/7) included colonies comprising a cluster of p53-positive cells surrounded by p53-negative ones. Each value represents the average of four separate experiments; the standard error is indicated. The total numbers of colonies scored in each case were as follows: H-175 control, 936 colonies; H-273 control, 1539 colonies; H-175+etoposide, 309 colonies; H-273+etoposide, 330 colonies. (b) Colony growth assay. Equal numbers of cells of the H-neo and H-175 pools were plated and stained as described in Materials and methods. Shown are three triplicate dishes of each pool in untreated cultures contained at least some mutant p53-overexpressing cells (empty bars, +/+ and +/7). The proportion of such colonies (slightly above 30%) was again very similar to that of individual p53-overexpressing cells within the initial mixed pool. However, when the plated H-175 cells were ®rst treated with etoposide and then allowed to recover, the proportion of resultant colonies exhibiting various degrees of p53 overexpression now became much higher, reaching a total of about 75% (®lled bars, +/+ and +/7). Hence, colonies overexpressing p53His175 but not p53His273 are selectively enriched in etoposide-treated cultures.
The enrichment for p53His175 colonies could potentially be due to a faster intrinsic growth rate of such colonies, rather than to increased chemoresistance. To rule out this possibility, a comparative colony formation assay was performed on untreated cultures. As seen in Figure 2b , no dierence in either colony number or average colony size was found between the H-175 and control H-neo pools.
Taken together, these results imply that overexpression of p53His175, but not p53His273, provides a selective clonogenic survival advantage to H1299 cells exposed to the cytotoxic action of etoposide.
Mutant p53 confers selective resistance to the apoptotic eect of etoposide
A possible explanation for the results described above could be that p53His175 confers a protective eect against etoposide-induced apoptosis. To explore this possibility, cells of each transfected pool were treated with etoposide and sorted in the FACS according to their p53 content. To that end, cells were ®rst stained with p53-speci®c antibodies. Then, using a standard gating procedure (Haupt et al., 1995 ; see also Figure  4 ), each population was resolved into high (H) and low (L) p53 expressors, the latter probably corresponding to cells staining negative for p53 in Figure 1b . As expected, high expressors were not detected in the pool transfected with vector only (H-neo). The high and low expressor sub-populations within a given pool were then each analysed separately for the presence of cells with sub-G1 DNA content, indicative of apoptosis (Haupt et al., 1995; Darzynkiewicz, 1995) . This protocol, which takes advantage of the mixed nature of each pool, allows direct comparison between cells which express abundant mutant p53 and those which express very little or none at all, all maintained within the same culture and under exactly identical experimental conditions. Consequently, the analysis is unaected by experiment-to-experiment¯uctuations in the kinetics and extent of apoptosis.
The results of this FACS analysis are shown in Figure 3a . In untreated cultures, the cell cycle distribution was practically identical between the high and low p53 expressors (data not shown), and was indistinguishable from that of parental H1299 cells. Exposure to 10 mM etoposide induced extensive apoptosis in vector-transfected H1299 cells (H-neo); over 40% of the cells displayed sub-diploid DNA content after 48 h of treatment. In addition, a prominent accumulation of cells in G2 was seen. A very similar pro®le was revealed by the low expressor sub-populations of both p53His175 and p53His273 transfected pools (H-175,L and H-273,L, respectively) . By contrast, a dramatic reduction in apoptosis was seen in the high expressor suppopulation (H) of the H-175 pool. Remarkably, while cells overexpressing p53His273 also appeared to sustain attenuated apoptosis, this apparent protective eect was much milder than with p53His175. p53His179 also conferred substantial protection against etoposide-induced apop- Figure 3 Stable overexpression of mutant p53 confers increased resistance to cell killing by etoposide. Each of the indicated stably transfected H1299 cell pools was either exposed to 10 mM etoposide for 48 h or left untreated, and then subjected to¯ow cytometric DNA content analysis (see Materials and methods). Brie¯y, ®xed cells were stained with propidium iodide (PI) and with p53-speci®c antibodies. Each population was ®rst resolved into high (H) and low (L) p53 expressors, and then each of these two sub-populations was analysed separately for DNA content (PI staining). (a) DNA content pro®les. Pool denominations are as in Figure 1a . Indicated below are the positions of cells with G1 and G2/M DNA content, as well as of cells with sub-G1 DNA content, taken to be apoptotic. Percentages of cells with sub-G1 DNA content are indicated above the corresponding horizontal bars. For untreated cultures, only the low expressor fraction is shown; the high expressor fractions exhibited practically identical cell cycle distributions, including a similar very low rate of background apoptosis (data not shown). (b) Compilation of data from several experiments of the type shown in a. Filled and empty bars denote the low and high p53 expressor sub-populations, respectively. Each bar represents the average of at least three separate experiments; in most cases, data was acquired from two independent pools of H1299 cells transfected with the same p53 mutant. The standard error is indicated tosis when overexpressed in H1299 cells, although its eect was somewhat less pronounced than that of p53H175 (Figure 3a) . On the other hand p53Trp248 was relatively ineective, similar to p53His273. A compilation of data from multiple experiments, employing two independent pools of each mutant, is shown in Figure 3b .
A similar picture was obtained for H1299 cells transfected transiently with plasmid encoding p53His175, when the culture was analysed for p53 expression and subsequently for DNA content ( Figure  4) . As expected for transient transfection, there were fewer high p53 producers; yet, these cells were signi®cantly refractory to killing by etoposide, similar to their stably transfected counterparts. Taken together, all the above ®ndings indicate that p53His175, and to a somewhat lesser extent also p53His179, confers upon H1299 cells substantial protection against etoposide cytotoxicity.
Mutant p53 confers resistance to low but not high concentrations of cisplatin
We next wished to ®nd out whether the dierent p53 mutants could also aect the cellular response to another anti-cancer drug, whose biochemical mechanism of action is very dierent from that of etoposide.
To that end, we performed a clonogenic survival assay on the stably transfected H1299 pools following treatment for 72 h with cisplatin (cis-DDP). As seen in Figure 5a , left panels, mutant p53 was indeed able to confer partial protection also against cis-DDP, when applied at the relatively low concentration of 2.5 mg/ ml; this was re¯ected by an enrichment of p53-positive colonies to about 60 ± 70% of the total, as compared to around 30 ± 35% in untreated cells. Figure 5b shows representative examples of the three dierent classes of colonies obtained in this experiment. However, unlike the very dierent eects of p53His175 and p53His273 on etoposide resistance, in the case of cis-DDP the two types of p53 mutants displayed very similar protective capacities; cells overexpressing p53His273 were enriched as eciently as those overexpressing p53His175. This was closely correlated with a similar ability of both mutants to protect H1299 against induction of apoptosis by this concentration of cis-DDP, when analysed at the end of a 72 h treatment period ( Figure  6a) .
A markedly dierent picture was revealed when cells were exposed to 10 mg/ml of cis-DDP. This high concentration completely abolished the ability of H1299 to give rise to growing colonies, irrespective of whether or not they expressed any mutant p53; consequently, no colonies whatsoever were obtained in the clonogenic survival assay (Figure 5a , right panels). This remained unchanged even after a longer recovery period of up to 30 days post cis-DDP treatment (data not shown), implying that the eect of cis-DDP is irreversible. Analysis of apoptosis after 48 h of exposure to 10 mg/ml cis-DDP revealed that none of the two mutants had any protective eect, unlike the situation seen with 2.5 mg/ml of the drug. This is consistent with the inability of these mutants to oer a detectable advantage in the clonogenic survival assay (Figure 5a) . Surprisingly, the overall fraction of cells with sub-G1 DNA content was actually lower than with 2.5 mg/ml, and a similar picture was seen also when the cis-DDP treated cultures were examined after longer or shorter treatments with 10 mg/ml cis-DDP (data not shown). This suggests that H1299 respond to this high cis-DDP concentration in a very dierent way than to the other drug treatments studied here. This could either involve an atypical type of death, with reduced DNA fragmentation and/or DNA loss, or else a failure to activate a proper death response owing to general irreversible cell`paralysis'. In either event, this unusual response is not altered by overexpressed mutant p53.
Discussion
We describe here a new function of mutant p53 proteins overexpressed frequently in human cancer. This is manifested as increased resistance to etoposide and cisplatin (cis-DDP), two agents commonly employed for cancer chemotherapy. A similar picture has recently been described for murine leukemic M1 cells, where overexpression of the mouse p53vall35 mutant caused increased resistance to apoptosis induced by cisplatin, doxorubicin or g-irradiation (Li et al., 1998) . It is conceivable that not all cell types may Figure 4 Transient overexpression of mutant p53 confers increased resistance to cell killing by etoposide. A culture of H1299 cells was transfected transiently with p53His175 expression plasmid (5 mg/10 cm dish). Twenty-four hours later, etoposide was added to a concentration of 10 mM for an additional 48 h. Cultures were analysed for p53 expression levels (left panel); p53¯uorescence is plotted forward scatter, serving as an approximation of cell size (forward scatter). The horizontal bar was set arbitrarily as the boundary between low (L) and high (H) p53 expressors; the same cut-o was also used to de®ne the H and L sub-populations throughout the experiments in Figure 3a and b. Each of the indicated sub-populations was monitored separately for DNA content distribution (right panels) behave identically to H1299, as suggested by the fact that certain tumors and cell lines fail to exhibit positive coupling between p53 mutations and increased chemoand radioresistance (Makris et al., 1995; Mathieu et al., 1995; Cote et al., 1997; Ribiero et al., 1997) .
Biological gain of function of mutant p53 has been demonstrated in a number of experimental models (e.g. Wolf et al., 1984; Dittmer et al., 1993; Hsiao et al., 1994) . Several recent studies have provided additional support for this important concept, as well as new Figure 5 Clonogenic survival assay of H-175 versus H-273 without or with cisplatin treatment. Experimental details were exactly as in Figure 2 , except that the indicated stably transfected H1299 pools were treated for 72 h with either 2.5 mg/ml or 10 mg/ml cisplatin (cis-DDP), and then the drug was removed and the cells were allowed to form colonies for another 14 days. (a) Clonogenic survival data; see legend of Figure 2a for further details. The total numbers of colonies scored in each case were as follows: H-175 control, 872 colonies; H-273 control, 1070 colonies; H-175+2.5 mg/ml cis-DDP, 360 colonies; H-273+2.5 mg/ml cis-DDP, 560 colonies. (b) The three types of colonies obtained in the clonogenic survival assay. Each panel depicts a segment of one representative colony, containing either only mutant p53-overexpressing cells (+/+), or a mixture of p53-positive and negative cells (+/7), or only p53-negative cells (7/7). Further details as in Figure 1b insights into the underlying molecular mechanisms. Lanyi et al (1998) reported that the C-terminal portion of p53, including the nonsequence-speci®c DNA binding domain and the oligomerization domain, is essential for the ability of mutant p53 to endow transfected cells with the ability to induce tumors in mice. The C-terminus was also required, along with the N-terminal transactivation domain and the hydrophobic core domain of p53, for activation of several promoters by mutant p53 proteins (Lanyi et al., 1998) . A very interesting new activity of mutant p53 was described by Gualberto et al., (1998) , who found that certain mutant p53 proteins can directly contribute to genomic instability by abrogating the mitotic spindle checkpoint in human cells, thereby leading to polyploidy and eventual aneuploidy. Of note, only conformational mutants like p53His/175 but not DNA contact mutants like p53Trp248 were capable of disrupting the spindle checkpoint (Gualberto et al., 1998) . This is remarkably reminiscent of the dierent eects of these mutants on etoposide resistance, as revealed in our analysis. It remains to be determined whether there exists a mechanistic relationship between these two types of gain of function.
The molecular mechanism underlying this new biological activity of mutant p53 remains to be elucidated. Mutant p53 can upregulate the expression of a variety of genes (e.g. Chin et al., 1992; Deb et al., 1992; Dittmer et al., 1993; Tsutsumi-Ishi et al., 1995; Ludes-Meyers et al., 1996) . Very recently, the c-myc oncogene was shown to be a potent target of many mutant p53 proteins, possibly accounting for some of their tumorigenic eects (Frazier et al., 1998) . It is thus possible that mutant p53 also alters the expression of genes associated with control of chemotherapy-induced cell death in H1299 cells. Certain p53 mutants can activate the promoter of the multidrug resistance (MDR1) gene (Chin et al., 1992) . Such activation might account in principle for the apparent antiapoptotic eect, by preventing the buildup of eective intracellular drug concentrations. However, several facts argue against such mechanistic explanation. First, we could not detect an increase in MDR1 mRNA in the transfected pools (data not shown). Secondly, p53His175 overexpression did not aect the ability of etoposide to enforce a G2 arrest (see Figure  3a) , arguing that the drug was being eciently delivered into the cell. Thirdly, both p53His273 and p53Trp248, which do not protect eciently against etoposide, induces the MDR1 promoter at least as potently as p53His175 (Dittmer et al., 1993) . Finally, resistance to cis-DDP can not be provided by the MDR1 glycoprotein, but was nevertheless conferred by mutant p53 proteins in our experiments. Hence, if p53His175 acts through transcriptional regulation, its relevant targets are likely to be genes other than MDR1. An obvious possibility would be upregulation of anti-apoptotic genes, or repression of pro-apoptotic ones. In this regard, a previous study did not ®nd correlations between p53 mutations and expression of several apoptosis-regulatory genes in drug-resistant lung cancer cell lines (Reeve et al., 1996) . It thus remains possible that the anti-apoptotic gain of function is mediated through a biochemical mechanism independent of gene-speci®c transcriptional regulation. One attractive possibility is that the mutant p53 protein binds and sequesters particular proteins required for ecient apoptosis. Possible candidates could be XPB and XPD (Wang et al., 1996) , or putative proteins interacting with the polyproline domain of p53 (Walker and Levine 1996; Sakamuro et al., 1997) . The ability of dierent p53 mutants to alter the serum-dependence of leukemic K562 cells was recently evaluated (Kremenetskaya et al., 1997) . Interestingly, it was found that p53His175 as well as several other mutants, but not p53His273 and p53Trp248, rendered these cells less dependent on serum survival factors. The striking similarity between the dierential behavior of these p53 mutants in two very dierent experimental systems strengthens the notion that mutants such as p53His175 may exert a broad anti-apoptotic eect on cancer cells.
Our data show clearly that dierent p53 mutants can vary widely with regard to chemoprotective potency Figure 6 Stable overexpression of mutant p53 confers increased resistance to cell killing by low but not high concentrations of cisplatin. The indicated stably transfected H1299 cell pools were treated with either 2.5 mg/ml (a) or 10 mg/ml (b) of cisplatin (cis-DDP). Cell cycle pro®les were determined after 72 h of treatment, as detailed in Figure 3a . Only the treated cells are shown; for untreated cell pro®les, see Figure 3a against de®ned agents. This dierential behavior depends on the exact site of the mutation, the identity of the drug, and also the concentration of the drug. In the case of etoposide, mutations such as His175 and His179, which alter the overall conformation of p53 (Milner 1995) , are far more potent than Trp248 and His273 which disrupt speci®c p53-DNA interactions without altering the overall protein conformation. In contrast, both classes of p53 mutants are equally capable of oering increased resistance to low concentrations of cis-DDP. Our data suggest that tumors harboring particular p53 mutations may be less responsive to particular anticancer agents. Of note, a non-random association between speci®c p53 mutations on the one hand and greater chemoresistance and worse prognosis on the other hand, has been described for colorectal cancer (Goh et al., 1995) , breast cancer (Borresen et al., 1995; Bergh et al., 1995; Aas et al., 1996) , ovarian cancer (Righetti et al., 1996) and soft tissue sarcomas (Traubert et al., 1996) . There is only partial overlap between the mutations de®ned as more`severe' in those studies and in the present one; this might be due to dierences between various tumor types, as well as the use of distinct chemotherapeutic drugs.
In conclusion, our ®ndings imply that the presence of particular p53 mutations may render a tumor less responsive to particular therapy regimens. These ®ndings should be extended to additional cell lines and extensive clinical data need to be collected and evaluated carefully in order to con®rm the in vivo relevance of the ®ndings. Eventually, this may provide important clues towards better therapy decisions.
Materials and methods
Cell lines, plasmids and transfections
The H1299 cell line is derived from a human large cell lung carcinoma (Mitsudomi et al., 1992) . H1299 cells were maintained in RPMI medium, supplemented with 10% fetal calf serum (FCS). The human p53 mutants used for transfections were described by Hinds et al., 1990) . Expression of all mutants was under transcriptional control of the CMV enhancer/promoter. Before transfection, the culture medium was changed to DMEM supplemented with 10% FCS. Transfections were done by the calcium phosphate method (Haupt et al., 1995) . Following transfection, the medium was changed again to RPMI+10% FCS, and stably transfected clones were selected in the presence of 0.4 mg/ml G418 for 1 week.
Western blot analysis
Cells were lysed directly in protein sample buer, loaded on a 12.5% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. The blot was probed with a mixture of the human p53-speci®c monoclonal antibodies PAb1801 and DO-1 and visualized with the aid of the ECL kit (Amersham).
Indirect immuno¯uorescence
Cells growing on glass coverslips were ®xed with cold methanol and incubated at 7208C for 30 min. After rehidratation with PBS for 5 min, the cells were stained for 1 h with a mixture of PAb 1801 and DO-1. Staining with the secondary antibody and with DAPI were performed as described before (Haupt et al., 1995) , followed by visualization under a¯uorescence microscope.
Colony growth assay
Cells were seeded at a density of 2000 per 60 mm dish. One week later colonies were ®xed in methanol at room temperature and stained with Giemsa solution followed by washing with water.
Clonogenic survival assay
Cells growing on glass coverslips (5610 5 cells per 100 mm dish containing nine glass coverslips) were treated with 10 mM etoposide for 48 h or with 2.5/10 mg cis-DDP for 72 h. Cells were then washed twice in PBS and replenished with fresh RPMI +10% FCS. Two weeks later the glass coverslips were ®xed in cold methanol and stained as described above. Colonies were visualized and scored under a¯uorescence microscope.
For untreated controls, 1610 4 cells were similarly plated on glass coverslips; colonies were ®xed and stained 1 week later.
Flow cytometry
For FACS analysis, adherent and detached cells were combined. Cells were ®xed, reacted with a mixture of PAb1801 and DO-1 (1 : 50) for 1 h at room temperature and stained with the secondary antibody and with propidium iodide (25 mg/ml; Sigma) as described before (Haupt et al., 1995) . Cells were analysed in a FACSORT cell sorter (Becton Dickinson). Gating for high and low p53 expressors was as described before (Haupt et al., 1995) .
